Iscalimab
Based on 1 Customer Validation
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.64%
- No. CAS: 2031153-61-2
- Peso molecular:146.08 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
CD40 0.3 nM (IC50) |
In Vitro
Iscalimab (0.01-1 μg/mL, overnight) blocks rCD154-induced TNF production by primary monocyte-derived dendritic cells (moDCs), with an IC50 of 0.04 μg/mL[3].
Iscalimab (3 days) inhibits rCD154-induced proliferation of PBMCs from humans, rhesus and cynomolgus animals with IC50s of 0.02, 0.03, and 0.01 μg/mL, respectively[3].
Iscalimab bind CD40 on B cells from humans, rhesus and cynomolgus animals with EC50 values of approximately 0.2 μg/mL[3].
Iscalimab (2 μg/mL, 3 h) is internalized by B cells in a CD40-dependent manner[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PBMCs from humans, rhesus and cynomolgus animals
-
Concentration:0-1 μg/mL approximately
-
Incubation Time:3 days
-
Result:Inhibited rCD154-induced proliferation of PBMCs with IC50s of 0.02, 0.03, and 0.01 μg/mL, respectively.
In Vivo
Iscalimab (10 mg/kg, i.v.) completely inhibits T cell-dependent antibody response in Rhesus monkeys[3].
Iscalimab (30 mg/kg, i.v.) prolongs allograft survival in kidney transplant cynomolgus[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kidney transplant cynomolgus[4]
-
Dosage:30 mg/kg
-
Administration:i.v.
-
Result:Prolonged allograft survival.
Well-tolerated with no evidence of thromboembolic events or CD40 pathway activation.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD40 Protein, Human can bind Iscalimab. The EC50 for this effect is 7.761 ng/mL. -
Flow Cytometry analysis of Raji cells labelling TNFRSF5/CD40 (red) with Iscalimab (anti-TNFRSF5/CD40) (HY-P99670). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
No. CAS 2031153-61-2
-
Appearance Liquid
-
Peso molecular 146.08 kDa
-
Color Colorless to light yellow
-
SMILES
[Iscalimab]
-
Synonyms
CFZ-533; OM11-62MF
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Kahaly GJ, et al. A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz013. [Content Brief]
[2]. Flandre TD, et al. Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study. Toxicol Pathol. 2022 Jul;50(5):712-724. [Content Brief]
[3]. Ristov J, et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant. 2018 Dec;18(12):2895-2904. [Content Brief]
[4]. Cordoba F, et al. A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion. Am J Transplant. 2015 Nov;15(11):2825-36. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Iscalimab Related Classifications
HY-P99670 Related Classifications
Powered by Bioz